Insmed Adds Staff for Follow-On Biologics Market
Insmed Inc., based in Richmond, announced that Steve Glover, 48, has joined Insmed’s management team as president of the newly-formed Follow-on Biologics business. Mr. Glover will be responsible for leading the development of Insmed’s follow-on biologics capability and its emerging portfolio of biogeneric/biosimilar products. “Insmed’s advanced knowledge of biologics development, its manufacturing capability, and its skilled scientific and technical workforce to make it the first U.S.-based biotechnology company to develop a comprehensive portfolio of follow-on biologics,” said Mr. Glover. “This is an organization that knows the drug industry is on the threshold of its second generic revolution.”
Prior to joining Insmed, he held the position of senior vice president and general manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. Dr. Geoffrey Allan, president and CEO of Insmed, said that Mr. Glover “will play a pivotal role in our follow-on biologics strategy, which together with the development of our approved flagship product IPLEX(TM) in niche markets, forms a dual-path approach for success.”
